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Background. Oxygen mitochondrial effects consumption by
the kidney (QO2), is linearly related to sodium reabsorption
(Tna), but recent studies suggest this relationship is variable
and that metabolic efficiency (QO2/Tna) in kidney is regulated
by hormonal factors. In the dog, nonselective inhibitors of nitric
oxide synthase (NOS) increase QO2 and QO2/Tna. Glomerular
hemodynamic and reabsorptive consequences of NOS inhibi-
tion require angiotensin II (Ang II), implying an antagonistic
relationship between nitric oxide and Ang II. Effects of NOS
inhibition in the rat, the role of Ang II and the responsible NOS
isoform have not been elucidated.
Methods. Kidney blood flow [renal blood flow (RBF)],
glomerular filtration rate (GFR), and QO2/Tna were mea-
sured before and during intravenous administration of NG-
monomethyl-L-arginine (L-NMMA), a nonselective NOS
inhibitor, in control and losartan (Ang II receptor blocker)-
treated rats and rats administered S-methyl-L-thiocitrulline
(SMTC), a NOS-1 inhibitor. Effects of SMTC on oxygen con-
sumption were also examined in freshly harvested proximal
tubules.
Results. L-NMMA and high-dose SMTC decreased RBF, but
L-NMMA + losartan and low-dose SMTC did not. QO2/Tna
increased in both L-NMMA groups. Both low- and high-dose
SMTC also increased QO2/Tna. SMTC increased QO2 in proxi-
mal tubules in vitro at presumed lower levels of vectorial NaCl
transport. Results suggest this effect was not mediated by influ-
ences on sodium transport alone.
Conclusion. Nonselective NOS inhibition increases the oxy-
gen costs of kidney function independent of Ang II. Kidney
NOS-1 is responsible for these in vivo and in vitro effects. In
vitro observations suggest that NOS-1 acts in part via effects on
basal metabolism and mitochondrial function.
Energy utilization by the kidney, as indexed by kidney
oxygen consumption, is primarily devoted to the process
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of NaCl and NaHCO3 reabsorption [1, 2]. The obligations
for kidney reabsorption are largely dictated by the filtered
load of sodium and its major anions as a consequence
of glomerulotubular balance [3, 4] and tubuloglomerular
feedback systems [5, 6], matching glomerular filtration
rate (GFR) and reabsorptive processes. Since GFR has
been shown renal plasma flow dependent, and therefore
renal blood flow (RBF) dependent [7, 8], the oxygen and
substrate demands for reabsorption are linked to the oxy-
gen and substrate supply via RBF in a rather complex
and somewhat circular context unique to the kidney. In
other organs, such as the heart, an increase in energy re-
quirements for increased cardiac work is universally and
predictably met by an increase in blood flow delivering
oxygen and nutrients. This resolution of increased de-
mand by enhanced supply is not as simple or complete in
the kidney, since the parallel increase in GFR which ac-
companies RBF will also augment reabsorption and con-
sequently the adenosine triphosphate (ATP) and oxygen
required [9, 10].
Based on thermodynamic considerations, one can pre-
dict a linear dependence of oxygen mitochondrial effects
consumption by the kidney (QO2) on GFR, or rather
total sodium reabsorption [1]. However, recent reports
suggest that the slope of this sodium reabsorption (Tna)
relationship, QO2/Tna, is quite variable. Welch et al [11],
Chabrashvili et al [12], Kawada, Imai, and Karber [13],
and Welch et al [14, 15] have observed marked increases
in QO2/Tna in spontaneously hypertensive rats (SHRs)
and in a variety of high angiotensin II (Ang II) and low
nitric oxide conditions. SHR has been postulated as a de-
creased nitric oxide condition and renal artery clip hyper-
tension and Ang II infusion models high Ang II states, and
these conditions were characterized by elevated QO2/Tna.
Endothelial dysfunction might fall into the category of a
low nitric oxide and elevated Ang II state.
Several investigators have suggested that an elemen-
tal function of nitric oxide is the suppression of mi-
tochondrial metabolism via inhibition of cytochrome c
oxidase, and by other mechanisms [16–19]. Studies in the
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dog have shown that acute nonselective nitric oxide syn-
thase (NOS) inhibitors can paradoxically increase QO2 in
the kidney while reducing GFR [20]. These results sug-
gest that nitric oxide is an important regulator of kid-
ney oxygen consumption per sodium ion reabsorbed [21,
22]. Since nitric oxide exerts important direct influences
on renal function, it is logical to consider that other an-
tagonistic neurohumoral influences, such as Ang II, may
also exert effects upon kidney QO2 [23]. Nitric oxide is
a renal vasodilator, which along with the coordinated in-
fluences of other renal vasodilators and vasoconstrictors,
regulates kidney oxygen and substrate supply. Further ef-
fects of neurohumoral regulators on the metabolic costs
of tubular reabsorption may not be limited to regulation
of mitochondrial energetics. These neurohumoral factors
also influence the efficiency of tubular reabsorption and,
via multiple mechanisms, dictate the “metabolic cost” of
kidney function.
Prior studies from this laboratory have suggested a nat-
ural antagonistic relationship between Ang II and nitric
oxide, particularly with regard to the control of glomeru-
lar ultrafiltration and tubular reabsorption [23]. Acute
NOS inhibition causes reduction in RBF and proximal
tubular reabsorption in the rat, phenomena largely re-
versed by angiotensin II type 1 (AT-1) receptor blockade.
Similar reversal of changes in RBF, GFR, and tubular
reabsorption by either angiotensin-converting enzyme
(ACE) inhibitors or AT-1 receptor blockers was observed
in pathophysiologic conditions which exhibit reduced ni-
tric oxide generation [24–27]. Observations in these con-
ditions suggest a functional antagonism between nitric
oxide and Ang II at the level of glomerular hemodynam-
ics and tubular reabsorption. We have performed studies
to pursue the hypotheses that (1) the increase in QO2 for
sodium reabsorption after NOS inhibition is observed in
the rat and is expressed, at least in part, via actions of
Ang II and (2) the NOS-1 isoform, when inhibited, par-
ticipates in the increase in kidney QO2/Tna.
METHODS
Animal experiments described herein were conducted
in accordance with the NIH Guide for the Care and Use
of Animals in Research.
Animals and surgical preparation
Adult male Wistar rats (Harlan, Indianapolis, IN,
USA) weighing 300 to 350 g were maintained on stan-
dard rat chow and tap water until the day of the ex-
periment. Rats were anesthetized with an intraperitoneal
injection of the thiobarbiturate, Inactin (100 mg/kg) (Re-
search Biochemicals International, Natick, MA, USA)
and placed on a thermostatically controlled surgical ta-
ble to maintain body temperature at 37◦C. Catheters were
placed in the trachea (PE-240), left jugular vein (PE-50)
for infusion of Ringer saline and drugs. Right femoral
artery was catheterized with PE-50 tubing for collection
of blood and measurement of mean arterial pressure.
Urinary collection is by a catheter (PE-50) inserted into
the bladder. The left renal artery was separated from
renal vein through a midline incision of the abdomen
plus a flank incision. The left kidney blood flow (RBF)
(mL/min) was monitored by a perivascular ultrasonic
transit time flow probe (Transonics T206) (Ithaca, NY,
USA) connected to a computer for continuous recording
[28, 29]. A 23 gauge needle was bent at 90◦ and inserted
into the proximal left renal vein for sampling renal venous
blood. GFR(mL/min) was measured by urinary clearance
of 3H-inulin administered in Ringer saline (5 lCi/mL at
1.5 mL/hour) or calculated from RBF, hematocrit, and
filtration fraction (FF) calculated according to the Fick
principle by 3H-inulin content of arterial and renal ve-
nous plasma:
FF = (1 − renal venous inulin/arterial inulin)
GFR = RBF × (1 − hematocrit) × FF
Drug administration and blood gas measurement
After the surgical preparation, the animals were al-
lowed 120 minutes to recover with the Doppler flow
probe in place with stable blood pressure and RBF. Af-
ter the control period, group I rats [NG-monomethyl-
L-arginine (L-NMMA) treated] (N = 6) were given
an intravenous continuous infusion of NOS inhibitor,
L-NMMA (Calbiochem, San Diego, CA, USA), at
30 mg/kg/hour. Group II (losartan treated) (N = 6)
rats received an intravenous bolus of AT-1 receptor
blocker, losartan (10 mg/kg) (Merck, Whitehouse Sta-
tion, NJ, USA) plus L-NMMA. Group IIIA [S-methyl-
L-thiocitrulline (SMTC) treated] (N = 6) rats were given
a continuous infusion of NOS-1 inhibitor, SMTC (Alexis,
Lausen, Switzerland), at 2.7 mg/kg/hour. Group IIIB
(SMTC low dose) (N = 6) was also utilized whereby
SMTC was infused at a lower dose of 1.35 mg/kg/hour.
Blood samples were taken from the femoral artery
and renal vein before (control) and during drug ad-
ministration at 30 and 60 minutes for measurements
of timed hemoglobin (tHb), O2Hb, PO2, PCO2, pH,
[Na+], [K+], [HCO3] with a color spectrophotometer
(682 CO-Oximeter) (Instrumentation Laboratory, Lex-
ington, MA, USA). Oxygen content (O2ct) was calcu-
lated by the formula below:
O2ct(mL/mLblood)
= (1.39 × tHb × O2Hb% + PO2 × 0.003) ÷ 100
The total left kidney oxygen consumption (QO2)
(mL/min), was calculated from A-V difference in O2ct
multiplied by RBF. The cost of sodium transport
(QO2/Tna) is the ratio of total amount of renal QO2 over
the total amount of sodium reabsorbed(Tna). Tna is equal
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to the total amount of sodium filtered minus the amount
of sodium excreted in the urine (UNaV). The total amount
of sodium filtered (FNa) per minute is the product of GFR
and plasma sodium concentration (PNa) and UNaV is the
product of urinary sodium concentration (UNa) and uri-
nary flow rate (V):
FNa= GFR × PNa
We performed time controls for all critical parameters
(RBF, GFR, QO2, and QO2/Tna) in a separate group of
rats receiving no treatment during a control period and
for two 30-minute periods thereafter.
Isolation and purification of rat renal proximal tubules
Isolation and purification of rat renal proximal tubules
were accomplished according to previously published
methods [30–32] with some modifications. All solutions
were gassed with 95%O2 and 5% CO2 before use. Male
Wistar rats weighing 300 g were anesthetized with In-
actin (100 mg/kg, intraperitoneally). By cannulating the
abdominal aorta the kidneys were first flushed with 40 mL
cold solution A containing (in mmol/L, pH 7.1) NaCl 112,
NaHCO3 20, KCl 5, CaCl2 1.6, Na2HPO4 2, MgSO4 1.2,
glucose 5, Hepes 10, mannitol 10, glutamine 1, sodium bu-
tyrate 1, and sodium lactate 1 within 5 minutes and then
perfused with 30 mL warm buffer (37◦C) containing 60
mg collagenase (Type II) (Worthington, Lakewood, NJ,
USA) within 10 minutes. After in situ digestion the kid-
neys were decapsulated and renal cortices were dissected,
chopped, and placed into 15 mL solution A containing 30
mg collagenase at 37◦C for 5 minutes. Immediately after
tubules were separated from undigested tissue by strain-
ing through a sieve (opening 125 lm (Sieve 120) (U.S.A.
Standard Sieve Series, Newark, NJ, USA) wire (Wire,
Cloth Co., Newark, NJ, USA), 20 mL of cold solution A
containing 3.5 mL fetal bovine serum (FBS) was added to
terminate collagenase activity. The tubules were washed
with Dulbecco’s modified Eagles medium (DMEM)/F-12
media (Invitrogen, Carlsbad, CA, USA) three times by
centrifugation at 50g for 2 minutes. Proximal tubules were
purified from other nephron segments and glomeruli by
centrifugation on 45% Percoll at 15,000g for 30 minutes
at 4◦C in Sorvall RC 5B plus centrifuge (SA600 Ro-
tor). The proximal tubules were recovered from the low-
est band (<95%). After three washes with DMEM/F-12
media to remove the Percoll the proximal tubules were
resuspended in DMEM/F-12 medium containing 3.3%
bovine serum albumin (BSA) on ice for 20 minutes to
recover. After three washes with DMEM/F-12 medium
the proximal tubules from one rat were resuspended in 4
mL of cold chamber buffer [DMEM/F-12 supplemented
with 1 × Insulin-Transferrin-Selenium (Gibco, Carlsbad,
CA, USA), 2 mmol/L butyrate, 1 mmol/L glutamine, 1
mmol/L malate, and 1 mmol/L pyruvate] for QO2 studies.
The 100% Percoll was made by mixing nine parts of the
pure Percoll (Pharmacia Biotech, Piscataway, NJ, USA)
with 1 part of 10× phosphate-buffered saline (PBS). The
100% Percoll was then diluted with 1× PBS (NaH2PO4
1.9 mmol/L, Na2PO48.1 mmol/L, and NaCl 154 mmol/L)
into 45% Percoll.
QO2 measurement and calculation
QO2 (lmol/min/lg protein) was measured polaro-
graphically in a 0.6 mL chamber (Instech Laboratories,
Inc., Plymouth Meeting, PA, USA) with a water jacket
maintained at 37◦C by using a Clarke-type oxygen elec-
trode and an YSI model 5300 oxymeter (Yellow Spring
Instrument, Yellow Spring, OH, USA). The chamber was
filled with buffer and a baseline was recorded. 0.1 mL of
the proximal tubule suspension was then added to the
chamber for evaluation of QO2. Once a stable recording
(basal QO2) was achieved (3 minutes), SMTC was added
into the chamber through the port on the top of the cham-
ber using a pipette with an extra long tip (Myriad Indus-
tries, San Diego, CA, USA) to allow the deposition of
the drug near the bottom of the chamber for another 3-
to 6-minute recording. The final concentration of SMTC
was 310 lmol/L. After completion of the recording 0.1 mL
of tubular suspension was obtained from the chamber for
measurement of protein content using a kit from Bio-Rad
(Hercules, CA, USA).
QO2 was calculated as follows: Oxygen saturated con-
dition is considered at 100 units. Under this condition
the oxygen dissolved in the solution is 544 nmol/mL. The
chamber volume is 0.6 mL. Hence, 544 (nmol/mL) ×
0.6 (mL) ± 100 (units) = 3.264 (nmol/unit) = 3264
(pmol/unit). Therefore, QO2 (pmol/min/lg protein) =
3264 (pmol/unit) × slope (unit/second) × 60 ± total pro-
tein (lg).
RESULTS
Assessments of kidney hemodynamics and sodium
reabsorption
RBF and inulin clearance (GFR) were measured be-
fore and during the administration of NOS inhibitors, L-
NMMA in group I, L-NMMA plus losartan in group II,
and SMTC at two doses (2.7 and 1.35 mg/kg/hour) in
groups IIIA and B, respectively, over a period of approx-
imately 100 minutes. RBF was monitored continuously
with a transit time ultrasound flow probe. RBF and GFR
were not different during the baseline control periods
(Fig. 1).
The RBF and GFR responses to NOS inhibitors dif-
fered significantly among the respective experimental
groups. L-NMMA (group I) and high-dose SMTC (group
IIIA) produced significant although modest reductions
in RBF (15% to 20%) by 60 minutes. In group II, L-
NMMA plus losartan, there was no effect on RBF, but
GFR trended downward, similar to groups I and III A, but
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Fig. 1. Changes in renal blood flow (RBF)
and glomerular filtration rate (GFR) after
nitric oxide synthase (NOS) inhibition. (A
and B) RBF changes after NG-monomethyl-
L-arginine (L-NMMA) and S-methyl-L-
thiocitrulline (SMTC). L-NMMA alone
decreased RBF at 30 and 60 minutes as did
high-dose SMTC. Losartan plus L-NMMA
did decrease RBF significantly at 60 minutes
but prevented the major reductions during
L-NMMA. Low-dose SMTC (B) did not
affect RBF. (C) There was a trend for GFR to
decrease with L-NMMA but did not achieve
significance. However, high-dose SMTC (A)
significantly reduced GFR at 60 minutes.
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Fig. 2. Changes in blood pressure (BP) fol-
lowing nitric oxide synthase (NOS) inhibition.
(A) NG-monomethyl-L-arginine (L-NMMA)
increased blood pressure significantly, how-
ever, this effect was prevented by concurrent
administration of losartan. (B) Blood pres-
sure was modestly but significantly increased
by high-dose S-methyl-L-thiocitrulline SMTC
(A).
this did not achieve significance. Low-dose SMTC (group
IIIB) had no effect on either RBF or GFR. Mean arte-
rial pressure increased in group I during L-NMMA infu-
sion and more modestly in group IIIA, high-dose SMTC
(Fig. 2). In all experimental groups, kidney sodium reab-
sorption (Tna) paralleled changes in GFR. In rats serving
as time controls RBF (7.3 ± 0.3 to 7.6 ± 0.4 mL/min) and
GFR (1.2 ± 0.1 to 1.1 ± 0.1 mL/min) remained unchanged
from control period to values 60 minutes later.
These subtle but significant differences among groups
in the responses of RBF, GFR, and blood pressure are im-
portant in the interpretation of whether changes in these
renal functional parameters alone could contribute to the
changes in QO2 and QO2/Tna. As observed, they did not
exert independent effects on QO2/Tna.
QO2 and reabsorptive metabolic costs (QO2/Tna)
The baseline values for QO2 and QO2/Tna were re-
markably similar among all groups, suggesting that un-
der anesthetized conditions and after modest surgery
there remains good uniformity in oxygen consumption
and metabolic efficiency of kidney sodium reabsorption.
Time controls which received no treatments revealed
that QO2 remained unchanged (0.2 ± 0.02 to 0.17 ±
0.01 mL/min) between control period and 60 minutes
thereafter. QO2/Tna did not change over this time period
without treatment (1.19 ± 0.15 to 1.15 ± 0.13 mL/mmol)
signifying stability of the preparation. In general, QO2
trended upward in all experimental groups, but this did
not achieve statistical significance based upon P val-
ues required after adjustment for multiple intergroup
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Fig. 3. Kidney oxygen consumption (QO2) and oxygen consumption per sodium reabsorbed (QO2/Tna) after nitric oxide synthase (NOS) inhibition.
(A) There was a trend for QO2 to increase following NG-monomethyl-L-arginine (L-NMMA) administration but this did not achieve significance.
(B) QO2 also did not increase significantly during S-methyl-L-thiocitrulline (SMTC). (C and D) However, L-NMMA and L-NMMA plus losartan
both increased QO2/Tna at 30 and 60 minutes. Both doses of SMTC also increased Qo2/Tna. (D) The steady increase which achieves significance at
60 minutes.
comparisons. Since GFR and Tna trended downward
in most groups, QO2/Tna increased quite consistently
(Fig. 3), and did so in all experimental groups. In both
groups I and II, an increase in QO2/Tna occurred within
30 minutes after administration of L-NMMA. These stud-
ies demonstrate that (1) nonselective NOS inhibition
does increase QO2/Tna in the rat, as previously demon-
strated in the dog, and (2) inhibition of Ang II activity
does not prevent QO2/Tna from increasing during NOS
blockade. This is in contrast with the effects of systemic
NOS blockade on glomerular hemodynamics and tubular
reabsorption, which are highly Ang II dependent. Losar-
tan alone exerted no effect on QO2/Tna.
Application of the NOS-1 inhibitor, SMTC at both low
and high doses, also produced a nearly identical increase
in QO2/Tna by 60 minutes after infusion of this agent.
However, there were no significant changes at 30 min-
utes after SMTC at either dose of this agent. This may re-
flect either differences in the capacities of L-NMMA and
SMTC to enter critical sites of NOS activity in the kidney
or differing inhibitory properties related to the rate of ad-
ministration (Fig. 3). We utilized two different doses of
SMTC for specific reasons. High-dose SMTC produced
reductions in RBF and GFR which were nearly identical
to that observed with L-NMMA, and blood pressure did
increase during high-dose SMTC, but to a lesser degree
than after L-NMMA. Since high-dose SMTC had all of
the renal effects, but only part of the blood pressure effect
of L-NMMA, high-dose SMTC appeared to be semispe-
cific for the NOS 1 isoform, which affects renal hemo-
dynamics via tubuloglomerular feedback. But given that
blood pressure increased to some degree with high-dose
SMTC, there was likely some spillover to NOS 3. The
lower dose of SMTC did not affect RBF, GFR, or blood
pressure, suggesting a highly selective NOS-1 inhibition.
Sixty minutes of low-dose SMTC increased QO2/Tna to
the same extent as observed with L-NMMA or high-dose
SMTC. These results suggest that inhibition of NOS-1
mediates the vast majority of the QO2/Tna effects of NOS
inhibition.
QO2 in freshly harvested proximal tubules: NOS-1
inhibition
QO2 was evaluated in an airtight chamber into which
agents were instilled. In freshly harvested tubules QO2
was remarkably stable over time as reflected by a rel-
atively constant slope of decline in chamber oxygen
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SMTC Fig. 4. Oxygen consumption (QO2) mea-
sured in freshly harvested proximal convo-
luted tubules and the effects of nitric oxide
synthase (NOS)-1 inhibitor, S-methyl-L-
thiocitrulline (SMTC). When tubules are
added to the airtight chamber the slope of
decline in oxygen tension increases reflecting
the stability of the preparation. When SMTC
is added, the slope increases reflecting an in-
crease in QO2. The lines reflect the automated
approximation of the slope of decline in oxy-
gen tension. Therefore, the in vitro proximal
tubule effects of SMTC parallel the kidney ef-
fects observed in vivo
tension. The basal rate of QO2 was 48.4 ± 6.3 pmol
O2/min/ug tissue protein. After addition of SMTC
(318 lmol/L), the NOS-1 inhibitor, QO2 increased sig-
nificantly to 75.5 ± 15.6 pmol O2/min/lg protein(N = 12
from seven rats) (P < 0.02). Therefore, NOS-1 inhibitors
produced similar increases in QO2 in vitro in proximal
tubules as were observed in kidneys in vivo (Fig. 4). Vec-
torial transport of NaCl is undoubtedly reduced in prox-
imal tubules in vitro, compared to in vivo. It is therefore
likely that NOS-1 inhibitor effects are primarily indepen-
dent of effects on active sodium transport and efficiency
thereof and due to effects on basal metabolism or mito-
chondrial function.
DISCUSSION
Neurohumoral factors exert major influences upon kid-
ney metabolism and QO2 [10, 13, 15]. The major neurohu-
moral systems include nitric oxide, Ang II, and adrenergic
nerves, and regulation by these systems includes vaso-
constrictor and vasodilator capacities which determine
renal blood flow and glomerular ultrafiltration and the
rate of tubular reabsorption. These considerations dic-
tate the balance between supply and demand for oxygen
and metabolic substrates and therefore regulate the ad-
equacy of metabolic needs [9, 33]. Another more recent
consideration is the regulation of the overall efficiency of
kidney function. How much oxygen is required for kidney
function which is primarily utilized for tubular reabsorp-
tion? The current study has examined the oxygen costs of
the kidney as indexed by sodium reabsorption and specif-
ically the role of nitric oxide. The results demonstrate
that inhibition of NOS increases oxygen requirements
for kidney function in the rat, and that this finding does
not require the participation of Ang II. NOS-1 inhibition
contributes significantly to the observed increase in kid-
ney metabolic costs as indexed by sodium reabsorption
(QO2/Tna).
The biologic effects of nitric oxide which could affect
kidney QO2 are multiple and complex. Obviously nitric
oxide as a vasodilator exerts impacts upon RBF, thereby
determining oxygen and substrate supply, but such
effects should not directly alter the metabolic efficiency
of tubular reabsorption. Laycock et al [20] clearly
demonstrated an increase in kidney QO2/Tna, an index
of metabolic cost. We have observed similar findings
in the rat. These observations could be the result of
alterations in either (1) the site of sodium reabsorption
along the nephron, (2) changes in the efficiency of
transport mechanisms in a critical segment such as
the proximal tubule, or (3) effects on mitochondrial
energetics. Prior studies from our laboratory and others
suggest a positive effect of nitric oxide on proximal
tubular reabsorption. Administration of L-NMMA
produced a major reduction in proximal reabsorption
[23], an effect which could increase QO2/Tna by either
shifting reabsorption into less efficient nephron segments
beyond the proximal tubule or by reducing the passive
component of sodium reabsorption within the proximal
tubule [21]. Nitric oxide also acts as a “brake” on oxida-
tive metabolism at various sites. Nitric oxide interacts
with a wide variety of ferroporphyrin molecules which
influence cell metabolism [16], including inhibition of
cytochrome c oxidase and aconitase, a citric acid cycle
enzyme [17, 18]. Nitric oxide also inhibits mitochondrial
pyruvate uptake and can also inhibit complex I [nicoti-
namide adenine dinucleotide (NADH)-ubiquinone
oxidoreductase], complex II (succinate-ubiquinone
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oxidoreductase) and cytochrome b [19, 34]. The major
in vivo regulatory function of nitric oxide is primarily
mediated via effects upon cytochrome c oxidase because
this system is regulated within the normal physiologic
range of nitric oxide concentrations [17, 18].
Multiple publications have demonstrated an effective
physiologic antagonism between nitric oxide and Ang II.
The earliest observations relate to regulation of glomeru-
lar hemodynamics, whereby the physiologic effects of
nonselective NOS inhibition, reductions in RBF, nephron
filtration rate, and the glomerular ultrafiltration coeffi-
cient, can be eliminated by application of the AT-1 re-
ceptor blockers [23]. In addition, we observed that the
aforementioned reduction in proximal tubular reab-
sorption after application of L-NMMA was largely re-
versed by the administration of losartan, an AT-1 re-
ceptor blocker. In a variety of pathophysiologic models
in the rat, including (1) renal artery clip hypertension,
(2) experimental diabetes, (3) glomerulonephritis, and
(4) cyclosporine toxicity, the normal kidney vasodilatory
response to glycine infusion, a nitric oxide–dependent
event, is absent [24–27, 35]. Associated with the absence
of vasodilation and increase in GFR, proximal tubular
reabsorption decreases significantly in the pathophysio-
logic models after glycine. These abnormalities, presum-
ably related to altered nitric oxide status, are corrected
to normal glycine responses when rats are given either
ACE inhibitors or AT-1 receptor blockers. These stud-
ies, in a less direct fashion, imply a functional antagonism
between nitric oxide and Ang II.
Given the above relationships at the level of kidney
function, it was reasonable to consider the possibility of a
similar hormonal antagonism relating to the metabolic
activity of the kidney. Welch et al [11], Chabrashvili
et al [12], Kawada, Imai, and Karber [13], and Welch et
al [14, 15] have supplied valuable data on the issue of
nitric oxide and Ang II effects on kidney QO2 in a vari-
ety of spontaneous and induced forms of hypertension.
These investigators have verified the observation that the
pO2 in the renal cortex is rather low at 40 to 45 mm Hg
in the rat [11, 36]. They have observed increased values
for kidney QO2/Tna in the SHR and in Ang II–induced
hypertension [11–15]. In the SHR the slope of relation-
ship between Tna and QO2 is increased. This increase in
QO2 was reversed or normalized by application of either
inhibitors of Ang II activity or the antioxidant, tempol.
We have examined the effects of losartan in normal rats
infused with L-NMMA. In spite of the evidence for a nat-
ural antagonistic relationship between Ang II and nitric
oxide [23, 27], we found no evidence for a role for Ang
II in the observed increase in QO2/Tna after nonselective
NOS inhibition. The current studies were acute and in
normal rats. The studies mentioned above [11–15] were
largely chronic requiring more than a week of treatment
and in models of hypertension and major elevations in
Ang II and/or reductions in nitric oxide.
Which NOS isoform present in kidney confers the ef-
fects on oxidative efficiency and QO2? The current results
demonstrate that inhibition of the NOS-1 isoform confers
an effect on QO2/Tna approximately equal to that of L-
NMMA. We rechecked the findings by applying half the
initial dose of SMTC, a quantity we had observed did
not decrease RBF or elevate systemic blood pressure,
in order to ensure that there was no significant spillover
inhibition of other NOS isoforms. SMTC at both doses
significantly increased QO2/Tna by 60 minutes after ap-
plication. The result is surprising only because a minority
of cells in the kidney have been observed to express sig-
nificant NOS-1 [37, 38]. NOS-1 is certainly present in the
macula densa but also in other cells, efferent arteriole,
several cell types in the distal tubule and in the medulla.
However, it is possible that neuronal NOS is expressed
more extensively, as has been observed in the heart. In
studies in cardiac tissue, mitochondrial NOS is function-
ally significant and such activity is not demonstrable in
the NOS-1 null or knockout mouse, implying that NOS
within mitochondria may be of the neuronal NOS lineage
[39].
Studies conducted in vitro in freshly harvested prox-
imal tubules have helped clarify these issues. Tubules
exhibited optimal rates of QO2 compatible with prior
studies with oxidative conditions designed for proximal
tubules [30, 32]. Application of SMTC to these tubules
consistently increased QO2 by approximately 56%. These
in vitro studies provide additional insights into mecha-
nisms. The proximal tubule appears to be a major partic-
ipant in the effects of NOS-1 inhibition on QO2. Since
active, vectorial NaCl reabsorption is likely much re-
duced in the in vitro condition compared to in vivo, the
observed increase in QO2 is not solely due to changes in
the efficiency of NaCl transport. Rather, the results are
best explained by effects of NOS-1 inhibitors on basal
QO2 due to mitochondrial influences.
CONCLUSION
The current study demonstrates that inhibition of NOS
isoforms in the rat produces a major increase in kid-
ney QO2 factored by kidney sodium reabsorption. This
increase is not mediated by activity of Ang II in that
blockade of the AT-1 receptor did not prevent the ef-
fects of NOS inhibition. This result stands in contrast to
the antagonistic relationship observed between nitric ox-
ide and Ang II in affecting glomerular hemodynamics
and tubular reabsorption. Inhibition of kidney NOS-1
produced increases in QO2 per sodium ion reabsorbed
which were identical to that observed with nonselective
NOS inhibitors. NOS-1 inhibition increased QO2 in vitro
730 Deng et al: Kidney oxygen consumption and nitric oxide
in proximal tubules. Effects of NOS-1 in the kidney are
likely mediated by effects on basal metabolism and direct
effects of nitric oxide on mitochondrial function.
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